The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement (VBP) tender program, allowing winning manufacturers to modify key details such as the marketing authorization holder (MAH), manufacturing company, packaging specs, and supply arrangements under specific conditions. The changes aim to maintain supply stability while keeping the winning status intact.
Recent Adjustments
- Sugammadex Tender Round 10: Fujian Boro Pharmaceutical Research and Development Co. Ltd. was replaced by Xiamen Boma Pharmaceutical Co. Ltd. as the winning manufacturer, with Guangdong Sunho Pharmaceutical Co. Ltd. remaining as the commissioned manufacturer.
- CP Pharmaceutical Qingdao: The firm, which won bids for alfacalcidol, paricalcitol, and calcitriol in Rounds 5, 7, and 8, changed its name to Chia Tai Pharmaceutical (Qingdao) Co. Ltd., still under Sino Biopharma’s ownership.
- Supply Tweaks: Several products saw adjustments to commissioned manufacturing partners and supply prices to ensure continuity.
VBP Flexibility
The rules permit changes to MAHs, manufacturers, packaging, and company names if conditions such as mergers, acquisitions, or production capacity shifts are met. This flexibility aims to address supply chain disruptions while preserving the integrity of VBP agreements.-Fineline Info & Tech
Leave a Reply